Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.51 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.51 |
| ▸ | MAOB | P27338 | 1/20 | 0.50 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
| ▸ | GAA | P10253 | 2/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.49 |
| ▸ | LTA4H | P09960 | 1/20 | 0.49 |
| ▸ | ATM | Q13315 | 1/20 | 0.48 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.48 |
| ▸ | PKM | P14618 | 1/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31096458 | 0.93 | L3MBTL1 (0.59) | L3MBTL1KDM4EHRH3MAOBAOC3 | |
| SCHEMBL9721587 | 0.93 | L3MBTL1 (0.59) | L3MBTL1KDM4EHRH3MAOBAOC3 | |
| SCHEMBL7199882 | 0.91 | L3MBTL1 (0.57) | L3MBTL1KDM4EHRH3MAOBAOC3 | |
| SCHEMBL10043036 | 0.85 | L3MBTL1 (0.54) | L3MBTL1KDM4EMAOBAOC3ALDH1A1 | |
| SCHEMBL10458221 | 0.84 | L3MBTL1 (0.60) | L3MBTL1KDM4EHRH3MAOBAOC3 | |
| SCHEMBL72484 | 0.82 | L3MBTL1 (0.59) | L3MBTL1KDM4EHRH3MAOBAOC3 | |
| SCHEMBL40097 | 0.82 | L3MBTL1 (0.59) | L3MBTL1KDM4EHRH3MAOBAOC3 | |
| SCHEMBL3524104 | 0.82 | L3MBTL1 (0.59) | L3MBTL1KDM4EHRH3MAOBAOC3 | |
| SCHEMBL2091560 | 0.82 | L3MBTL1 (0.59) | L3MBTL1KDM4EHRH3MAOBAOC3 | |
| SCHEMBL585718 | 0.82 | L3MBTL1 (0.59) | L3MBTL1KDM4EHRH3MAOBAOC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111039929-A | Antitumor compound NY and series derivatives thereof | 中国人民解放军北部战区总医院 | 2020-04-21 | — | — | CN | disclosed |
| CN-100408575-C | Aryl-8-azabicyclo[3,2,1]octanes for treating depression | WYETH CORP (US) | 2008-08-06 | — | — | CN | disclosed |
| EP-1390364-B1 | ARYL-8-AZABICYCLO 3.2.1]OCTANES FOR THE TREATMENT OF DEPRESSION | WYETH CORP (US) | 2004-09-29 | — | — | EP | disclosed |
| CN-1509287-A | Aryl-8-azabicyclo[3,2,1]octanes for treating depression | — | 2004-06-30 | — | — | CN | disclosed |
| EP-1390364-A1 | ARYL-8-AZABICYCLO 3.2.1]OCTANES FOR THE TREATMENT OF DEPRESSION | Wyeth (US) | 2004-02-25 | — | — | EP | disclosed |
| US-6632824-B2 | Have the ability to act at the 5-HT transporter. | WYETH | 2003-10-14 | — | — | US | disclosed |
| US-20030032645-A1 | Aryl-8-azabicyclo [3.2.1] octanes for the treatment of depression | WYETH | 2003-02-13 | — | — | US | disclosed |
| WO-2002096906-A1 | ARYL-8-AZABICYCLO[3.2.1]OCTANES FOR THE TREATMENT OF DEPRESSION | WYETH (US) | 2002-12-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030032645-A1 | Aryl-8-azabicyclo [3.2.1] octanes for the treatment of depression | HTR1A, HTR1D, HTR2C | L3MBTL1 4800/4885KDM4E 404/4885HRH3 1181/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.